CHA2DS2-VASc Score
The CHA2DS2-VASc score estimates annual stroke risk in atrial fibrillation to guide anticoagulation decisions.
Indications for Use
Used to estimate stroke risk in atrial fibrillation and guide anticoagulation decisions. Identify low-risk patients (0 men, 1 women) who do not need OAC and initiate OAC when annual stroke risk is ≥2% (generally ≥2 men, ≥3 women) 1 [Level I evidence]. Helps determine therapy in clinical AF of any duration, including device‑detected AF when risk is ≥1–2%/yr 2 [Level I evidence].
Insights & Cautions
Incorporate overall stroke‑risk but interpret cautiously: absolute risk varies widely for the same score level and discrimination is only modest (pooled c‑statistic ~0.64 1 [Level I evidence]). Risk is often over‑ or underestimated across cohorts and particularly limited in renal disease and low‑risk patients (2023 ACC/AHA AF Guideline 2 [Level I evidence]). Use additional modifiers such as AF burden or uncontrolled hypertension to refine decisions.